Interesting. Such "skunk works" have existed in many industries, including pharma. But rarely have they existed on such a large scale.
Glaxo Mimics Carmaker to Speed Vaccine
GSK Bio adopted a similar tactic and cut the development time of Cervarix in half. Instead of filing for approval at the end of 2008 as planned, "one roof" allowed GSK Bio to do it two-and-a-half years earlier than expected in Europe, and 18 months earlier in the U.S. If approved, as analysts expect it will be, Cervarix could be on the market in the U.S. within six months.
Comments